Sophiris Bio (SPHS) has risen sharply, recording gains of 89.85% in the past 4 weeks. However, the stock has corrected -5.96% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 87.91% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 4.23% and the 50-Day Moving Average is 63.08%. Sophiris Bio (NASDAQ:SPHS): On Fridays trading session , Opening price of the stock was $5.11 with an intraday high of $5.19. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.98. However, the stock managed to close at $5.05, a loss of 2.13% for the day. On the previous day, the stock had closed at $5.16. The total traded volume of the day was 789,274 shares.
The company Insiders own 5.9% of Sophiris Bio shares according to the proxy statements. Institutional Investors own 13.35% of Sophiris Bio shares.
Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.